Unum Stock Crashes 12% in a Single Day—What’s Behind the Bloodbath?

Another day, another trad-fi tantrum. Unum shares got bulldozed today—here’s why Wall Street’s hitting the panic button.

The Drop: No Soft Landing Here

12% evaporated faster than a DeFi rug pull. No earnings miss, no scandal—just pure, unfiltered market chaos.

Short Sellers or Sector Rot?

Healthcare stocks are bleeding, but Unum’s gushing. Either the algos smelled weakness or some hedge fund needed yacht fuel.

The Aftermath: Bagholders Wanted

‘Buy the dip’ crowd’s suspiciously quiet today. Maybe they’re too busy explaining 12% ‘temporary corrections’ to their clients.

Funny how traditional finance still pretends these moves are ‘unexpected’—while paying analysts seven figures to predict them.

Quite the whiff on the bottom line

In its second quarter, Unum took in revenue of $3.36 billion, which bettered the $3.23 billion of the same period of 2024. This was on the back of a nearly 5% year-over-year rise in premium income to $2.75 billion, and a 3% increase in net investment income to almost $561 million. The top-line figure was only slightly higher than the consensus analyst estimate of $3.33 billion.

Image source: Getty Images.

However, Unum's after-tax adjusted operating income fell, sliding by 12% to slightly more than $361 million, or $2.07 per share. Prognosticators tracking the stock were expecting much better, as they were collectively modeling $2.22 per share.

Management attempted to put a positive spin on the quarter, quoting CEO Richard McKenney as saying that "Core fundamentals remain solid and we continued to deliver strong premium growth in our capital-efficient, high-return businesses."

Yet another chop

A larger factor in the Unum sell-off was the company's full-year profitability guidance, which was reduced for the second quarter in a row. Over the entirety of 2025, Unum is now modeling an after-tax adjusted operating income of $8.50 per share, which WOULD be less than 1% higher than the 2024 result. Previously, Unum had forecast growth of at least 6% in the line item.